ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-like kinase 7 being developed as a potential treatment for obesity. The results were presented in a poster ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase ...

State of New Jersey Common Pension Fund D raised its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...